长按二维码,关注官方公众号
You can share it to WeChat via the Qr code.
Enter the applet sharing event using WeChat scan.
Background
"If the 20th century was the era of drug therapy, then the 21st century is the era of cell therapy," George Daley said, a biologist from the USA. Cell and gene therapies (CGT), represented by CAR-T, have shown tremendous potential in many diseases, especially cancer and genetic diseases, giving rise to the CGCT. In the past two forums, we have discussed cutting-edge technology, built an industry chain for T-cell therapy production and clinical applications, and explored emerging cell therapies, gene editing and therapy, mRNA drug development and production, and oncolytic virotherapy. Nearly 2,000 participants have gained a lot.
The CGCT forum always escorts practitioners in the cell and gene industry. The Third China Gene & Cell Therapy Innovation Forum (CGCT 2023), jointly organized by Professional Committee of Medical Engineering Transformation and Healthcare Industry Integration of China Research Hospital Association，Porton Advanced, BioValley, and BioBAY, will be held in Suzhou on June 9th. to June 10th., 2023. We will continue to focus on the forefront of Chinese cellular and genetic immunotherapy academically, explore and share new achievements in CGT with all parties and discuss the new era of the CGT field in a broader manner.
The commercialization of drugs is the closest link between drugs and ordinary patients, while CGT in combination therapy makes up for the deficiencies and is a thorough way to conquer diseases. Therefore, we will share and discuss drug commercialization strategies on combination therapy, covering the whole stage of CGT from the development of cutting-edge technology to industrial cooperation, which is also the goal of the CGCT forum. The conference will also invite well-known capital investors to join forces with colleagues from the industry, allowing all participants to leave satisfied and helping the colleagues in the CGT industry to develop together and create brilliance.
In the misty and rainy south of the Yangtze river, we return to the time-honored city - Suzhou. May new success in 2023!
Brief
Formu：The Third China Gene & Cell Therapy Innovation Forum
Theme：Accelerating the Transition into the Clinic and Beyond
Guider：National Center of Technology Innovation for Biopharmaceuticals
Organizers：Professional Committee of Medical Engineering Transformation and Healthcare Industry Integration of China Research Hospital Association，Porton Advanced, BioValley, BioBAY
Co-Organizer：University of Shanghai for Science and Technology-Shanghai Jiao Tong University School of Medicine, Institute for Interdisciplinary Innovation - Suzhou Institute of Biomedical Engineering and Technology
Supporting organizers："Innovation China" Sci-Tech Service Team for Biopharmaceutical Industry, Chinese Biopharmaceutical Association - CBA
Time：June. 9th-10th. 2023
Place：Suzhou, Jiangsu Province
Scale：1000人
Highlights
Participants of the previous conference
*
*Continuous update
· Previous Scale·
· Guests of the Previous Forum ·
· Types of Participants of the Previous Forum ·
· Comments from the Guests of the Previous Forum ·
· A Glance of the Previous Forum ·
Enterprises, brands and parks have gathered again to escort the rapid development of China's cell and gene enterprises
As the first national technological innovation center in the field ofbiomedicine approved by the National Center of Technolo?gy lnnovation for Biopharmaceuticals in March 2021, the National Center focuses on the key fields of biological drugs suchas antibodies, vaccines, nucleic acid drugs, cells and gene therapy, and accelerates the five key tasks" technology researchlatform construction. talent introduction and training. network construction and ecological construction " With Suzhoundustrial Park as the main base, Guochuang Center actively builds a global innovation network by combining and collaboating with the world's top innovation resources, and strives to become a world-class comprehensive technology innovationplatform for biological drugs and a national strategic science and technology force in the field of biological drugs.
Suzhou Boton Advanced. was established in December 2018, based in Suzhou Industrial Park, relying on the listed company - Chongqing Boton Pharmaceutical Technology Co., Ltd. (stock code: 300363), to build a CDMO platform such as plasmid, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and live bacterial therapy, providing end-to-end services from library construction, process method and analytical method development, cGMP production to formulation filling, through different stages of drug research and development. Help customers accelerate drug development and market development.
On the basis of the successful experience of BOTN Co., Ltd., with world-class professionals as the core, adhering to the service tenet of "customer first", taking "compliance, professionalism, focus, openness and collaboration" as the brand concept, continuing the parent company's strong IP protection and project management mechanism and perfect quality management system, making full use of the core team's successful experience in promoting gene and cell therapy products to the clinic to the market, providing high-quality and efficient services to global customers, so that good drugs can benefit the public earlier.
BioValley is born in 2016，a rapidly growing biopharma and biotechnology focused knowledgement community，headquartered in Shanghai. In the spirit of Expertise & Originality, BioValley is committed to providing the high-value knowledge, holistic consulting services, and precision marketing solutions to the entire biopharmaceutical industry.
BioValley has an omnichannel media matrix - “Biovalley”, “Biotitude”, -“Immunology Chat“,etc., with totally 300,000+ subscribers on Tiktok, TouTiao.com, Zhihu, etc. On this basis, we provide a complete knowledge service system and precise marketing solutions for the entire bio chain. BioValley has been recognized as a platform with “attitude, altitude, warmth”, a close liaison for all stakeholders on the value chain of this industry.
Suzhou BioBAY is a high-tech carrier for the incubation and development of biomedical industry in Suzhou Industrial Park, after more than ten years of deep cultivation and cultivation, BioBAY has gathered more than 500 biomedical high-tech innovation enterprises and nearly 15,000 high-level scientific and technological talents to form three key industrial clusters of innovative drug research and development, high-end medical devices and biotechnology, and strive to build a world-class bio-industry ecosystem.
